TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20491709
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g EPA for 15 weeks
Study: 11948003
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg ER
Study: 11948003
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg ER
Study: 11948003
Drug: ER formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER formulation
Study: 11948003
Drug: Higher ER
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher ER doses
Study: 7053922
Drug: Frusemide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (1 mg/kg)
Study: 7053922
Drug: Chlorthiazid (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthiazid (10 mg/Kg)
Study: 7053922
Drug: Frusemide (0.25‐0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (0.25‐0.5 mg/Kg)
Study: 7053922
Drug: Chlorthiazid (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthiazid (20 mg/Kg)
Study: 31374063
Drug: 0.05% cyclosporine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% cyclosporine ophthalmic emulsion (CsA OE)
Study: 26149189
Drug: l-carnitine 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-carnitine 750 mg/d for 8 weeks
Study: 21659360
Drug: Fludarabine, Chlorambucil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine, Chlorambucil, and Fludarabine with Cyclophosphamide as first-line treatment
Study: 12013322
Drug: Cardiovascular agents
Normalized name: CARDIOVASCULAR AGENTS,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiovascular agents
Study: 9864106
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion under the right hemidiaphragm (Group B)
Study: 9864106
Drug: Bupivacaine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 1.5 mg/kg infusion under the right hemidiaphragm (Group C)
Study: 9864106
Drug: Bupivacaine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine infusion with subhepatic drain (Group D)
Study: 9864106
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline plus bupivacaine infusion (Group E)
Study: 7016242
Drug: Lateral subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral subcutaneous sphincterotomy under general anaesthesia (n = 37)
Study: 7016242
Drug: Lateral subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral subcutaneous sphincterotomy under local anaesthesia (n = 34)
Study: 28954570
Drug: Solution-Focused Brief
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution-Focused Brief Couple Therapy (SFBCT)
Study: 25102328
Drug: Naltrexone (NTX)
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone (NTX) 25 mg/d for 8 weeks
Study: 21925716
Drug: AZD0837 (150,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0837 (150, 250 or 350 mg)
Study: 21925716
Drug: ximelagatran (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: ximelagatran (36 mg twice daily)
Study: 21925716
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonist (VKA) titrated to INR of 2-3
Study: 20806988
Drug: Guanfacine XR
Normalized name: guanfacine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine XR (1-4 mg/day)
Study: 12735532
Drug: Home therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home therapy
Study: 2180271
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 alone (group I)
Study: 2180271
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 and oral disulfiram 2000 mg/m2 (group II)
Study: 31069935
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (IAsp) (0.3 U/kg)
Study: 26502953
Drug: Rhodiola rosea
Normalized name: RHODIOLA ROSEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhodiola rosea L (2 × 200 mg dose Vitano®, 1 tablet taken before breakfast and 1 tablet before lunch)
Study: 15380963
Drug: Invasive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive treatment (angiography and intervention within 24 hours of thrombolysis)
Study: 9694317
Drug: Interval training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interval training at ventilatory threshold (Vth), walking/jogging sessions twice a week, duration increased from 30 min to 1 h over 3 months
Study: 8589465
Drug: 10% low
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% low molecular weight dextran at 25 mL/hr
Study: 2760258
Drug: Norfloxacin (NOR)
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norfloxacin (NOR) 800 mg/d
Study: 2760258
Drug: Ciprofloxacin (C)
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin (C) 1 g/d
Study: 2760258
Drug: Nalidixic acid
Normalized name: Nalidixic Acid
DrugBank: Nalidixic acid (DB00779)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalidixic acid (NAL) 2 g/d
Study: 29796671
Drug: Monosodium glutamate
Normalized name: Monosodium Glutamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monosodium glutamate (MSG) supplemented vegetable broth (3.8 g MSG daily for 4 weeks)
Study: 30207748
Drug: Technosphere insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Technosphere insulin (TI)
Study: 26180109
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (C)
Study: 22181827
Drug: QS ruby
Normalized name: Ruby arsenic
DrugBank: Tetraarsenic tetrasulfide (DB19141)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QS ruby laser, aggressive treatment (Group 1)
Study: 22181827
Drug: QS ruby
Normalized name: Ruby arsenic
DrugBank: Tetraarsenic tetrasulfide (DB19141)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QS ruby laser, mild treatment (Group 2)
Study: 22181827
Drug: QS frequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: QS frequency doubled Nd:YAG laser, aggressive treatment (Group 3)
Study: 22181827
Drug: QS frequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: QS frequency doubled Nd:YAG laser, mild treatment (Group 4)
Study: 20962614
Drug: Interferon‐α administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon‐α administration during structured treatment interruptions (STIs)
Study: 17459295
Drug: Topical diflucortolone
Normalized name: diflucortolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diflucortolone valerate 0.001 percent and oral cetirizine hydrochloride (Group A)
Study: 17459295
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin in addition to topical diflucortolone valerate and oral cetirizine hydrochloride (Group B)
Study: 17459295
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone or intralesional triamcinolone acetonide (for severe cases)
Study: 8927677
Drug: Nicotine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (7 mg/day for nonsmokers and 21 mg/day for smokers)
Study: 1642023
Drug: Diet and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and/or oral antidiabetics
Study: 26115881
Drug: HCV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV treatment
Study: 11113401
Drug: Pravastatin (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (combined with cholestyramine and/or nicotinic acid) to achieve LDL cholesterol levels of < or =130 mg/dl (group A)
Study: 11113401
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group B) with antilipidemic therapy determined by family physicians
Study: 11113401
Drug: Pravastatin-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin-based therapy (group A)
Study: 3297472
Drug: Caffeine 360
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine 360 mg
Study: 3297472
Drug: Caffeine >90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine >90 mg
Study: 3297472
Drug: Caffeine (dose-related)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (dose-related)
Study: 3297472
Drug: Caffeine (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (not dose-related)
Study: 31327670
Drug: Aerosolized 15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized 15% xylitol (5 ml) twice a day for 14 days
Study: 31327670
Drug: Aerosolized 7%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized 7% hypertonic saline (4 ml) twice a day for 14 days
Study: 29211295
Drug: FOLFOX/Bev (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX/Bev (for TS-L tumors)
Study: 27350298
Drug: Control (conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (conservative treatment)
Study: 23163143
Drug: Comprehensive protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive protocol of integrative medicine (naomai jiejing decoction No. 1 and No. 2)
Study: 23163143
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy and nimodipine (control group)
Study: 18032857
Drug: Oral terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbinafine 250 mg, one tablet twice daily for seven days every month (pulse therapy)
Study: 18032857
Drug: Oral terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbinafine pulse therapy plus topical ciclopirox olamine 8% applied once daily at night
Study: 18032857
Drug: Oral terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbinafine pulse therapy plus topical amorolfine hydrochloride 5% applied once weekly at night
Study: 16151607
Drug: KTP 532-nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KTP 532-nm laser treatment with pulse duration (PD) varying from 0.13 to 1.71 times thermal relaxation time (Tr)
Study: 16151607
Drug: KTP 532-nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KTP 532-nm laser treatment with PD near or higher than Tr
Study: 11967748
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% with sufentanil 2 microgram/ml
Study: 11967748
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% with sufentanil 2 microgram/ml
Study: 1428294
Drug: Gallopamil 50
Normalized name: gallopamil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil 50 mg single-dose
Study: 1428294
Drug: Gallopamil 50
Normalized name: gallopamil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil 50 mg steady-state (after nine doses)
Study: 12766522
Drug: Implantable cardioverter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable cardioverter defibrillator (ICD) therapy
Study: 15294263
Drug: No ICD
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ICD therapy
Study: 26490053
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics (no-antibiotic group)
Study: 17664372
Drug: In-treatment LV
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-treatment LV hypertrophy absence (measured by CP and SLV)
Study: 17664372
Drug: In-treatment LV
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-treatment LV hypertrophy absence (measured by SLV)
Study: 17664372
Drug: In-treatment LV
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-treatment LV hypertrophy absence (measured by CP)
Study: 17664372
Drug: Absence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absence of in-treatment LV hypertrophy (by both SLV and CP)
Study: 6382987
Drug: Acebutolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (400 mg thrice daily)
Study: 6382987
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg thrice daily)
Study: 28789578
Drug: Accelerated intermittent
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated intermittent theta‐burst stimulation (aiTBS) treatment over the left dorsolateral prefrontal cortex (DLPFC)
Study: 22695239
Drug: Solabegron 125
Normalized name: Solabegron
DrugBank: Solabegron (DB06190)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solabegron 125 mg
Study: 9987165
Drug: Diphtheria antitoxin
Normalized name: Diphtheria Antitoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria antitoxin (> 0.01 IU ml‐1)
Study: 7567643
Drug: Lactitol (250-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactitol (250-400 mg/kg/day)
Study: 7567643
Drug: Lactulose (500-750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (500-750 mg/kg/day)
Study: 2187272
Drug: 4 litre
Normalized name: glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 litre regimen of a solution of electrolytes and polyethylenglycol
Study: 31455295
Drug: Remifentanil 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.3 μg/kg (diluted to 2 ml) 1 min before sufentanil injection
Study: 31455295
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (NS) 2 ml at the same time point as sufentanil injection
Study: 31455295
Drug: Remifentanil 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.3 μg/kg
Study: 20889287
Drug: Mild hypothermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild hypothermia therapy (body temperature maintained at 32.7°C for 72 hours)
Study: 17086911
Drug: Oromucosal cannabis-based
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oromucosal cannabis-based medicine (CBM)
Study: 15589385
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg QD
Study: 11759100
Drug: UltraSeal XT
Normalized name: Ultrasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: UltraSeal XT plus (filled sealant with drying agent)
Study: 9263279
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine supplementation after exhaustive exercise
Study: 11548448
Drug: Captopril (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25-50 mg b.i.d.)
Study: 18958167
Drug: Concurrent presentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent presentation of objective information about diseases
Study: 15723892
Drug: CBSM+ intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBSM+ intervention (10-week group cognitive-behavioral stress management/expressive supportive therapy)
Study: 12830458
Drug: T +
Normalized name: RE PreVit + DHA Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: T + V (Trandolapril 2 mg + Verapamil 180 mg)
Study: 12830458
Drug: T +
Normalized name: RE PreVit + DHA Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: T + A (Trandolapril 2 mg + Amlodipine 5 mg)
Study: 8895271
Drug: Ketorolac 60
Normalized name: ketorolac 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 60 mg (Group II)
Study: 6594786
Drug: Fluoride-containing sucking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride-containing sucking tablet (Fludent, 0.25 mg F) daily at bedtime for 3 years
Study: 6594786
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no fluoride tablet)
Study: 29071950
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (3 months duration)
Study: 29071950
Drug: Routine rehabilitation
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine rehabilitation therapy (Control group)
Study: 17900364
Drug: Whole milk
Normalized name: Calcium fortified whole milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole milk (710 ml daily for one month)
Study: 17900364
Drug: Low fat
Normalized name: Low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fat (2%) milk (710 ml for one week)
Study: 12090906
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg (R)-carvedilol
Study: 12090906
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg (S)-carvedilol
Study: 12090906
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg (R,S)-carvedilol
Study: 12090906
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg (R,S)-carvedilol (in patients with essential arterial hypertension)
Study: 7675047
Drug: DTP toxoids
Normalized name: DIPHTHERIA TOXOID
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP toxoids after two doses
Study: 7029988
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 2 g/die for 30 days
Study: 30856025
Drug: Fennel infusion
Normalized name: Fennel
DrugBank: Fennel (DB15615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fennel infusion plus dry cupping
Study: 25172889
Drug: ET receptor
Normalized name: P2Y12 G-protein-coupled platelet receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: ET receptor blockade (bosentan)
Study: 15573192
Drug: Dexamethasone 0.5mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.5mg/kg intravenous
Study: 26550815
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with passive cycling (PC)
Study: 12135314
Drug: Amlodipine (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (calcium antagonist)
Study: 17068625
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia followed with postoperative intravenous analgesia (n=53)
Study: 12941494
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention on generic drugs (verbal information and handout materials)
Study: 10642232
Drug: Plasma N‐terminal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma N‐terminal atrial natriuretic peptide >0.8 nmol/l
Study: 9342765
Drug: 1800 mg
Normalized name: glycerin 1800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800 mg LI 160/die
Study: 9342765
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg imipramine/die
Study: 3097159
Drug: Terfenadine (sufficient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (sufficient dose to cause maximum H1 receptor blockade)
Study: 3097159
Drug: Histamine (acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine (acting on the H1 receptor)
Study: 28836154
Drug: Moderate hypothermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate hypothermia (MH, n = 40, nasopharyngeal temperature 25 °C, rectal temperature 28 °C)
Study: 28836154
Drug: Deep hypothermia
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep hypothermia (DH, n = 42, nasopharyngeal temperature 20 °C, rectal temperature 25 °C)
Study: 23385272
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection plus physiotherapy
Study: 23953523
Drug: Reduced-dose tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose tacrolimus plus sirolimus (rTAC)
Study: 23953523
Drug: Standard-dose tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose tacrolimus and sirolimus (sTAC)
Study: 17852727
Drug: Sequential retrieval
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential retrieval order
Study: 15871445
Drug: Celecoxib (Celebrex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (Celebrex 200 mg, Pfizer, Turkey)
Study: 11789239
Drug: Rhinitis Spray
Normalized name: sodium chloride Nasal Spray [Rhinaris]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhinitis Spray (RS)
Study: 9169300
Drug: Haloperidol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (15 +/- 5 mg/day)
Study: 9376336
Drug: Olanzapine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5 +/- 2.5 mg/day)
Study: 9376336
Drug: Olanzapine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10 +/- 2.5 mg/day)
Study: 9376336
Drug: Olanzapine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (15 +/- 2.5 mg/day)
Study: 8258676
Drug: Lisinopril (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10-40 mg/day)
Study: 8258676
Drug: Nifedipine (30-90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (30-90 mg/day)
Study: 3937666
Drug: Sustak-forte preparation
Normalized name: Erythroped Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustak-forte preparation (nitroglycerin with prolonged action)
Study: 30675708
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg for 6 months
Study: 27407100
Drug: Bevacizumab combination
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab combination arm
Study: 20495588
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg intravenous ketamine infusion diluted in 500 cc normal saline over a 5 hour period daily for one week and 300 mg of gabapentin 3 times daily.
Study: 20495588
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion and 300 mg of gabapentin 3 times daily.
Study: 8431046
Drug: Intercostal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intercostal bupivacaine (0.5% bupivacaine, 360 mg/day)